The last decade has seen a substantial increase in research focused on the identification of
blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based …

Purpose To make recommendations regarding the use of bisphosphonates and other bone-
modifying agents as adjuvant therapy for patients with breast cancer. Methods Cancer Care …

Background Bone is the most common site of metastatic disease associated with breast
cancer (BC). Bisphosphonates inhibit osteoclast‐mediated bone resorption, and novel …

Cancer-induced bone disease is a major source of morbidity and mortality in cancer
patients. Thus, effective bone-targeted therapies are essential to improve disease-free …

Bone is the most common site for metastasis in patients with solid tumours.
Bisphosphonates are an effective treatment for preventing skeletal related events and …

Metastasis to bone, and indeed potentially to other sites, results from the numerous
interactions between cancer cells, haematopoietic stem cells and normal bone cells within …

Abstract Background Bisphosphonates (BPs) are pyrophosphate analogues widely used in
diseases related to bone loss and increased bone turnover. Their high affinity for bone …

Purpose The addition of bisphosphonates to adjuvant therapy improves survival in
postmenopausal breast cancer (BC) patients. We report a meta-analysis of four randomised …

Neoadjuvant treatment of breast cancer: maximizing pathologi... : Current Opinion in Obstetrics
and Gynecology Neoadjuvant treatment of breast cancer: maximizing pathologic complete …

This study sought to determine if there was an association between prognostic-based serum
biomarkers, survival, and psychosocial factors in patients with metastatic renal cell …